These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27437869)

  • 1. Prognostic impact of MYH9 expression on patients with acute myeloid leukemia.
    Yu M; Wang J; Zhu Z; Hu C; Ma Q; Li X; Yin X; Huang J; Zhang T; Ma Z; Zhou Y; Li C; Chen F; Chen J; Wang Y; Pan H; Wang D; Jin J
    Oncotarget; 2017 Jan; 8(1):156-163. PubMed ID: 27437869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.
    Wang J; Yu M; Guo Q; Ma Q; Hu C; Ma Z; Yin X; Li X; Wang Y; Pan H; Wang D; Huang J; Meng H; Tong H; Qian W; Jin J
    Sci Rep; 2017 Apr; 7():45960. PubMed ID: 28452374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.
    Chen YK; Hou HA; Tang JL; Jhuang JY; Lai YJ; Lee MC; Kuo YY; Chou WC; Liu CY; Lin CW; Chuang SS; Chen CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    PLoS One; 2015; 10(3):e0119831. PubMed ID: 25794001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.
    Wang J; Li F; Ma Z; Yu M; Guo Q; Huang J; Yu W; Wang Y; Jin J
    EBioMedicine; 2018 Feb; 28():90-96. PubMed ID: 29402726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia in a child with hereditary thrombocytopenia.
    Rheingold SR
    Pediatr Blood Cancer; 2007 Jan; 48(1):105-7. PubMed ID: 16276527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
    Ma QL; Wang JH; Yang M; Wang HP; Jin J
    J Transl Med; 2018 Mar; 16(1):68. PubMed ID: 29540187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
    Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
    Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
    Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia.
    Hua S; Feng T; Yin L; Wang Q; Shao X
    J Cell Mol Med; 2021 Oct; 25(19):9331-9339. PubMed ID: 34432355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
    Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
    Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities.
    Zare-Abdollahi D; Safari S; Movafagh A; Ghadiani M; Tabarraee M; Riazi-Isfahani S; Gorji S; Keyvan L; Gachkar L
    Int J Lab Hematol; 2016 Apr; 38(2):125-32. PubMed ID: 26765290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.